Clinical Trial

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Protocol Amendment History 2 changes
notable Trial sites expanded: 274 -> 278 locations 2026-08-11
notable Trial sites expanded: 267 -> 271 locations 2026-04-16
Trial Details
NCT Number NCT07361510
Lead Sponsor Bristol-Myers Squibb
Collaborators: BioNTech SE
Conditions Non-Small Cell Lung Cancer (NSCLC)
Enrollment 750 participants
Start Date 2026-03-12
Primary Completion 2031-10-14 (estimated)
Study Completion 2031-10-14 (estimated)
Updated on ClinicalTrials.gov 2026-08-10